Artelo Biosciences reports 2026 meeting votes

Artelo Biosciences, Inc. reported the results of its Annual Meeting of Stockholders held on July 17, 2026.

Rhea-AI Filing Summary

Artelo Biosciences, Inc. reported the results of its Annual Meeting of Stockholders held on July 17, 2026. As of the May 22, 2026 record date, 2,848,540 shares of common stock were outstanding, and 1,172,203 shares were represented at the meeting, approximately 41.2% of shares entitled to vote.

Stockholders cast votes for three director nominees: Gregory R. Reyes, M.D., Ph.D. (179,416 For; 55,405 Withhold; 937,382 broker non-votes), Tamara A. Favorito (176,821 For; 58,000 Withhold; 937,382 broker non-votes), and Gregory D. Gorgas (171,567 For; 63,254 Withhold; 937,382 broker non-votes). Two additional matters received 985,717 For, 164,845 Against, 21,641 Abstain on one proposal, and 91,158 For, 65,155 Against, 78,508 Abstain, with 937,382 broker non-votes, on another.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares outstanding at record date: 2,848,540 shares Shares represented at meeting: 1,172,203 shares Participation rate: 41.2% +5 more

8 metrics

Shares outstanding at record date 2,848,540 shares Common stock outstanding as of record date May 22, 2026

Shares represented at meeting 1,172,203 shares Shares present or represented by proxy at Annual Meeting

Participation rate 41.2% Approximate percentage of outstanding shares represented at the meeting

Votes for Reyes 179,416 For Director nominee Gregory R. Reyes, M.D., Ph.D.

Votes for Favorito 176,821 For Director nominee Tamara A. Favorito

Votes for Gorgas 171,567 For Director nominee Gregory D. Gorgas

Proposal votes 985,717 For; 164,845 Against; 21,641 Abstain Vote totals on one non-director matter

Proposal with broker non-votes 91,158 For; 65,155 Against; 78,508 Abstain; 937,382 broker non-votes Vote totals on another matter

Key Terms

Annual Meeting of Stockholders, record date, broker non-votes, emerging growth company, +1 more

5 terms

Annual Meeting of Stockholders financial

"We held our Annual Meeting of Stockholders (the “Annual Meeting”)"

record date financial

"outstanding as of the record date of May 22, 2026"

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

broker non-votes financial

"Broker Non-Votes 937,382"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

virtual annual meeting technical

"by attending the virtual annual meeting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When did Artelo Biosciences (ARTL) hold its 2026 Annual Meeting of Stockholders?

Artelo Biosciences (ARTL) held its 2026 Annual Meeting of Stockholders on July 17, 2026. The meeting was conducted as a virtual annual meeting, and stockholders voted on director elections and other matters disclosed in the voting results.

How many Artelo Biosciences (ARTL) shares were outstanding and entitled to vote at the 2026 meeting?

As of the May 22, 2026 record date, Artelo Biosciences (ARTL) had 2,848,540 shares of common stock outstanding and entitled to vote. These shares formed the basis for calculating quorum and voting percentages at the Annual Meeting.

What percentage of Artelo Biosciences (ARTL) shares were represented at the 2026 Annual Meeting?

At the 2026 Annual Meeting, 1,172,203 Artelo Biosciences (ARTL) shares were represented, approximately 41.2% of the outstanding common stock. Shares were represented either by proxy or by stockholders attending the virtual meeting.

What were the vote totals for Artelo Biosciences (ARTL) director nominee Gregory R. Reyes?

For director nominee Gregory R. Reyes, M.D., Ph.D., Artelo Biosciences (ARTL) reported 179,416 votes For, 55,405 votes Withhold, and 937,382 broker non-votes. The For votes exceeded the Withhold votes based on these tallies.

How did Artelo Biosciences (ARTL) stockholders vote on one of the non-director proposals?

For one proposal, Artelo Biosciences (ARTL) stockholders cast 985,717 votes For, 164,845 votes Against, and 21,641 Abstain. The company also reported a separate proposal with its own For, Against, Abstain, and broker non-vote totals.

What broker non-votes did Artelo Biosciences (ARTL) report for certain 2026 meeting items?

Artelo Biosciences (ARTL) reported 937,382 broker non-votes for the director elections and one additional proposal. Broker non-votes represent shares held by brokers that did not receive voting instructions on specific non-routine items.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/17/2026 - 04:35 PM Accepted by SEC EDGAR 07/17/2026 - 04:34 PM Learn about SEC filing dates

0001621221false00016212212026-07-172026-07-17iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 17, 2026

ARTELO BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-38951		33-1220924
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

505 Lomas Santa Fe, Suite 160  Solana Beach, CA USA		92075
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (858) 925-7049

___________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ARTL		The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 5.07 Submission of Matters to a Vote of Security Holders.

We held our Annual Meeting of Stockholders (the “Annual Meeting”) on July 17, 2026. Of the 2,848,540 shares of our common stock, par value $0.001 (“Common Stock”), outstanding as of the record date of May 22, 2026, 1,172,203 shares of Common Stock were represented at the Annual Meeting, either by proxy or by attending the virtual annual meeting, constituting, of the shares entitled to vote, approximately 41.2% of the outstanding shares of Common Stock. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below.

1. Election of Three Class III Directors. The following nominees were re-elected by the holders of our common stock to serve as our Class III directors until our 2029 annual meeting of stockholders and until their successors have been duly elected and qualified:

Nominee		For		Withhold		Broker Non-Votes
Gregory R. Reyes, M.D., Ph.D.		179,416		55,405		937,382
Tamara A. Favorito		176,821		58,000		937,382
Gregory D. Gorgas		171,567		63,254		937,382

2.  Approval of an Amendment to the Articles of Incorporation. The amendment to our Articles of Incorporation, as amended, to increase the number of authorized shares of our common stock from 166,666,667 to 500,000,000 was approved based on the following results of voting:

For		Against		Abstain
985,717		164,845		21,641

3.  Share Issuance Approval. The issuance of more than 20% of our issued and outstanding common stock pursuant to our Equity Purchase Agreement with Square Gate Capital Master Fund, LLC – Series 5 was approved based on the following results of voting:

For		Against		Abstain		Broker Non-Votes
91,158		65,155		78,508		937,382

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ARTELO BIOSCIENCES, INC.
Date: July 17, 2026	/s/ Gregory D. Gorgas
	Gregory D. Gorgas
	President & Chief Executive Officer

3

Filing Exhibits & Attachments

5 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 4.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 14.8 KB
• EX-101 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE 898 B
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 9.4 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 2.0 KB